Serum cuts vaccine price for states to Rs 300/dose
"As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward," Adar Poonawalla said
Serum Institute of India (SII) -- the maker of the most used COVID-19 vaccine in the country -- on Wednesday announced a cut in price of the jab it plans to sell to states to Rs 300 per dose from the earlier Rs 400.
This follows widespread criticism of its pricing policy as it had sold the initial doses of Covishield to the central government at Rs 150 per dose.
SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.
"As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives," he said.
A public interest litigation (PIL) has been filed in the Bombay High Court challenging the different rates for COVID-19 vaccines for the Centre and state governments and requesting direction to the Serum Institute of India (SSI) and Bharat Biotech to sell their vaccines at a uniform rate of Rs 150 per dose.
The PIL, filed on April 24 by advocate Fayzan Khan and three law students, said the vaccine is presumed to be an essential commodity and hence its management and distribution cannot be left in the hands of private companies.
"These pharma giants are milking the fear psychosis of the increased death rates due to COVID-19," it said.
Under the third phase of the national vaccination drive commencing next month, the vaccine manufacturers would supply 50 percent of their monthly Central Drugs Laboratory (CDL) released doses to the central government and would be free to supply the remaining 50 percent doses to state governments and in the open market, the government had said.
"In a situation where the entire country is gripped with the COVID-19 pandemic, price control by the government is a must and such kind of loot and blackmail should not be permitted," it said.
The PIL also questioned the propriety of (the Centre) in asking state governments to compete in the open market for vaccines.
"Both the state as well as the Central government have the constitutional obligation to protect the health of a citizen and there cannot be any discrimination. Asking state governments to compete in the open market for vaccine procurement with the Centre and private hospitals is not correct," the plea said.
It further said that the cost difference would also lead to discrimination between different states.
"Experience shows that the BJP-led state governments would be supplied the vaccine by the Central government but non-BJP ruling states would not be supplied and they would be forced to purchase the vaccines at a higher rate," the petitioners said.
The plea requested the HC to quash and set aside the prices declared by the SII for Covishield and by the Bharat Biotech for Covaxin.
It further sought a direction for the vaccine rates to be fixed at a uniform rate of Rs 150 (plus GST) for all the citizens.
"Combating the coronavirus is in the national interest and private entities like the Serum Institute of India should not be given any control over the health of a citizen. The Union and state governments have sovereign powers for management, control, production and equitable distribution and inoculation of the vaccine," the plea said.
The PIL further said the SII was selling the vaccines at Rs 150 (plus GST) for the Central government, Rs 400 for the state government and Rs 600 for private hospitals.
Edited by Anju Narayanan
